

TRIUS THERAPEUTICS - Partnering or Buy Out = Upside

<https://marketpublishers.com/r/T8AAF334916EN.html>

Date: March 2013

Pages: 4

Price: US\$ 90.00 (Single User License)

ID: T8AAF334916EN

Abstracts

Positive top line data of Tedizolid (oral/IV, 2nd-generation oxazolidinone, PhIII, Acute Bacterial Skin and Skin Structure Infections – ABSSSI; PhII, CAP/HAP/Bacteremia, partnered with Bayer for Asian, LA and ME rights) from 2nd pivotal PhIII study (ESTABLISH 2, Table 1A/1B) increases the probability of approval by 1H14 in US in ABSSSI indication. We expect Tedizolid to achieve switching from Zyvox (intolerant, deep tissue infections where long term treatment is required – pulmonary setting etc) and vancomycin (non-responsive and renal impaired). Partnership/Acquisition could happen despite threat by generic Zyvox as the demand of new and potent antibiotics is growing due to ... For more detail, please read our initiation report released on 26th March, 2013 on Trius (TSRX) titled “Partnering or Buy Out = Upside”

Companies mentioned

Trius Therapeutics

I would like to order

Product name: TRIUS THERAPEUTICS - Partnering or Buy Out = Upside

Product link: <https://marketpublishers.com/r/T8AAF334916EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T8AAF334916EN.html>